Noopur Raje, MD, discusses future research with bispecific T-cell engagers in multiple myeloma.
Noopur Raje, MD, director of the Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, and a professor of medicine at Harvard Medical School, discusses future research with bispecific T-cell engagers (BiTEs) in multiple myeloma.
The clinical development of BiTEs in the multiple myeloma space is still in such early stages, says Raje. The exciting part is that deep and durable responses are being observed in patients with refractory disease. The safety profile of these antibodies needs to be better understood along with what the most convenient route of treatment for patients is going to be, adds Raje. The question of whether over time the frequency of these BiTEs can be decreased is another one that needs to be addressed with future research. Ongoing clinical trials are going to be crucial in answering some of those questions, concludes Raje.